Laura Palmeri
Overview
Explore the profile of Laura Palmeri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
993
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Cosimo S, Tagliaferri B, Generali D, Giudici F, Agustoni F, Bernardo A, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33809465
Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT)...
2.
Amatu A, Schirripa M, Tosi F, Lonardi S, Bencardino K, Bonazzina E, et al.
Front Oncol
. 2019 Jul;
9:622.
PMID: 31355139
Regorafenib improves progression free survival (PFS) in a subset of metastatic colorectal cancer (mCRC) patients, although no biomarkers of efficacy are available. Circulating methylated DNA (cmDNA) assessed by a five-gene...
3.
Mauri G, Pizzutilo E, Amatu A, Bencardino K, Palmeri L, Bonazzina E, et al.
Cancer Treat Rev
. 2019 Jan;
73:41-53.
PMID: 30616224
Background: Despite advances in precision oncology and immunotherapy of tumors, little progress has been made in metastatic colorectal cancer (mCRC) in recent years. Therefore, making the most of available therapies...
4.
Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, et al.
Target Oncol
. 2017 Jul;
12(4):525-533.
PMID: 28669023
Background: Patients with metastatic colorectal cancer (mCRC) refractory to standard therapies have a poor prognosis. In this setting, recruitment into clinical trials is warranted, and studies driven by selection according...
5.
Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J, et al.
Cancer Discov
. 2017 Feb;
7(4):400-409.
PMID: 28183697
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients...
6.
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al.
Lancet Oncol
. 2016 Apr;
17(6):738-746.
PMID: 27108243
Background: We previously found that dual HER2 blockade with trastuzumab and lapatinib led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic colorectal cancer. In this study, we...
7.
Bencardino K, Mauri G, Amatu A, Tosi F, Bonazzina E, Palmeri L, et al.
Clin Colorectal Cancer
. 2016 Mar;
15(3):213-21.
PMID: 26979913
Oxaliplatin immune-induced syndrome (OIIS) is an uncommon, potentially life-threatening, side effect associated with oxaliplatin-based chemotherapy. The present study reports 5 original cases of OIIS and systematically reviewed the available published...
8.
Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, et al.
J Natl Cancer Inst
. 2015 Nov;
108(1).
PMID: 26563355
In metastatic colorectal cancer (CRC), actionable genetic lesions represent potential clinical opportunities. NTRK1, 2, and 3 gene rearrangements encode oncogenic fusions of the tropomyosin-receptor kinase (TRK) family of receptor tyrosine...
9.
Palmeri S, Berretta M, Palmeri L
Anticancer Agents Med Chem
. 2013 Oct;
13(9):1325-31.
PMID: 24168149
We performed a bibliographic electronic search of MEDLINE and Cochrane databases on breast cancer in the elderly. In the adjuvant setting aromatase inhibitors are more effective than tamoxifen with an...
10.
Cabibbo G, Palmeri L, Palmeri S, Craxi A
Liver Int
. 2011 Nov;
32(1):21-7.
PMID: 22098398
Cirrhosis is a major cause of morbidity and mortality and is the end stage of any chronic liver disease. Cancer, a leading cause of death worldwide, is a growing global...